EP4208032A1 - Verfahren zur herstellung von kolostrumkonzentrat - Google Patents
Verfahren zur herstellung von kolostrumkonzentratInfo
- Publication number
- EP4208032A1 EP4208032A1 EP21778224.2A EP21778224A EP4208032A1 EP 4208032 A1 EP4208032 A1 EP 4208032A1 EP 21778224 A EP21778224 A EP 21778224A EP 4208032 A1 EP4208032 A1 EP 4208032A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- colostrum
- process according
- fact
- concentrate
- mbar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000003022 colostrum Anatomy 0.000 title claims abstract description 73
- 235000021277 colostrum Nutrition 0.000 title claims abstract description 73
- 238000000034 method Methods 0.000 title claims abstract description 49
- 230000008569 process Effects 0.000 title claims abstract description 44
- 239000012141 concentrate Substances 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 238000001704 evaporation Methods 0.000 claims description 4
- 230000008020 evaporation Effects 0.000 claims description 4
- 230000017423 tissue regeneration Effects 0.000 claims description 4
- ZOEGQXCAXOUFHN-UHFFFAOYSA-N Furosin Natural products OC1C2OC(=O)C(C=3C4C5(O)O)=CC(O)=C(O)C=3OC5(O)C(=O)C=C4C(=O)OC1C(CO)OC2OC(=O)C1=CC(O)=C(O)C(O)=C1 ZOEGQXCAXOUFHN-UHFFFAOYSA-N 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 230000005484 gravity Effects 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims description 2
- 208000025865 Ulcer Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 238000001471 micro-filtration Methods 0.000 claims description 2
- 230000002906 microbiologic effect Effects 0.000 claims description 2
- 230000009854 mucosal lesion Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000011069 regeneration method Methods 0.000 claims description 2
- 231100000444 skin lesion Toxicity 0.000 claims description 2
- 206010040882 skin lesion Diseases 0.000 claims description 2
- 230000006641 stabilisation Effects 0.000 claims description 2
- 238000011105 stabilization Methods 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 231100000397 ulcer Toxicity 0.000 claims description 2
- CXTMLIMZRPKULL-YXYYPBJFSA-N dnc013643 Chemical compound O([C@@H]1O[C@@H]([C@H]2OC(=O)C=3[C@@H]4C(C(C(=O)C=3)(O)O)(O)OC=3C(O)=C(O)C=C(C4=3)C(=O)O[C@@H]1[C@H]2O)CO)C(=O)C1=CC(O)=C(O)C(O)=C1 CXTMLIMZRPKULL-YXYYPBJFSA-N 0.000 claims 1
- 239000003181 biological factor Substances 0.000 description 5
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- YQHPCDPFXQXCMV-VIFPVBQESA-N (2s)-2-amino-6-[[2-(furan-2-yl)-2-oxoethyl]amino]hexanoic acid Chemical compound OC(=O)[C@@H](N)CCCCNCC(=O)C1=CC=CO1 YQHPCDPFXQXCMV-VIFPVBQESA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 238000001223 reverse osmosis Methods 0.000 description 2
- 239000011885 synergistic combination Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102100032241 Lactotransferrin Human genes 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- -1 TGF01 Proteins 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
- A23C9/206—Colostrum; Human milk
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Definitions
- the present invention relates to a process for the preparation of colostrums concentrate.
- serum, placenta and colostrum contain numerous biologically active factors, e.g. vital protein factors such as cytokines, growth factors, chemotactic factors, complement factors and other active components.
- vital protein factors such as cytokines, growth factors, chemotactic factors, complement factors and other active components.
- biologically active factors or “active biological factors” relates to components that have a certain biological activity, including all substances that have a therapeutic or beneficial effect on the body.
- Colostrum is particularly rich in these factors, which are in particular INFy, TNFa, TGF01, IGF-1, immunoglobulins such as IgG, IgM and IgA, IL-2 and complement factors C3A and C4A.
- the main aim of the present invention is to provide a process for the preparation of colostrum concentrate which makes it possible to keep the biologically active components of native colostrum unaltered.
- One object of the present invention is to provide a process for the preparation of colostrum concentrate which has low operating times, compared to known processes, allowing the biological effectiveness of the components contained therein to be maintained.
- Another object of the present invention is to devise a process for the preparation of colostrum concentrate which enables the aforementioned drawbacks of the prior art to be overcome within the framework of a simple, rational, easy and effective to use as well as affordable solution.
- the objects mentioned above are achieved by the colostrum concentrate having the characteristics of claim 12.
- the present invention relates to a process for the preparation of colostrum concentrate.
- the process comprises the following phases of: a) supply of colostrum; b) concentration of colostrum comprising the steps of: bi) subjecting colostrum to controlled vacuum conditions; bi) applying a temperature lower than 45°C to colostrum.
- colostrum is supplied whole in the hours following delivery.
- colostrum is collected in the hours immediately after delivery, i.e., within 36 hours of delivery.
- colostrum is collected within 24 hours of delivery.
- colostrum is of bovine, equine or caprine origin.
- the supply phase involves freezing the colostrum.
- the colostrum supplied frozen undergoes melting at a temperature of between 4°C and 15°C.
- the supply phase involves supplying colostrum in a freeze-dried or dehydrated state.
- colostrum is solubilized in water.
- solubilization ratio between colostrum and water is between 30:70 and 60:40.
- controlled vacuum conditions comprise pressure values lower than the atmospheric pressure.
- such pressure values are lower than 300 mbar.
- such pressure values are lower than 150 mbar.
- the pressure values are comprised between 40 mbar and 80 mbar.
- the process comprises the step of applying temperature values comprised between 20°C and 40°C.
- the process comprises the step of applying temperature values comprised between 25°C and 35°C.
- such temperature values are lower than 30°C.
- the concentration phase comprises an evaporation step of the water contained in the colostrum.
- the evaporation step allows removing the water from the colostrum allowing it to be concentrated at a concentration ratio of 5:1 with respect to the native colostrum. This means that 1 kg of colostrum concentrate is obtained for 5 kg of native colostrum by carrying out the process according to the present invention.
- the concentration phase is carried out until a density value of colostrum comprised between 1,100 mg/kg and 1,250 mg/kg is reached.
- the process comprises an extraction phase of the latter.
- the aforementioned extraction phase is carried out through separation by gravity.
- This separation by gravity is achieved by means of centrifugation at 10,000 RPM for an operating time of substantially 120 seconds.
- the aforementioned extraction phase is carried out by reverse osmosis.
- reverse osmosis also known as hyperfiltration, is the process whereby solvent molecules, in the present case residual water, are forced from the more concentrated solution, in the present case colostrum concentrate, to the less concentrated solution obtained by applying a pressure greater than the osmotic pressure to the colostrum concentrate.
- the process comprises a microbiological stabilization phase of the colostrum concentrate carried out through one of: UV rays, microfiltration, ozone flow and high pressure treatment.
- the present invention relates to colostrum concentrate obtainable from the process described above and having a furosine content of less than 0.1 mg/lOOg of colostrum concentrate.
- the aforementioned colostrum has a density lower than 5 kg/1, preferably lower than 2 kg/1.
- Example 1 Qualitative-quantitative analysis of colostrum concentrate obtained by the process according to the invention.
- Table 1 shows a furosine content of less than 0.1 mg/lOOg colostrum.
- the process described in the present invention offers the advantage of obtaining colostrum concentrate characterized by the presence of active biological factors comprising immunoglobulins specific to the animal species from which it is derived and which may be used for therapeutic purposes.
- the process according to the present invention offers the advantage of obtaining the aforementioned active biological factors in a biologically active form, thanks to the non-use of any treatment which could cause denaturation of the proteins and modification of their tertiary structure, such as high temperatures or low pH values.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising colostrum obtained from the previously described process together with other pharmacologically acceptable excipients and/or adjuvants.
- composition is suitable for topical application or oral administration.
- composition is suitable for use in the treatment of diseases requiring tissue repair or regeneration, the latter being selected from the list comprising: ulcers, skin lesions and mucosal lesions.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102020000020971A IT202000020971A1 (it) | 2020-09-03 | 2020-09-03 | Procedimento per la preparazione di colostro concentrato |
| PCT/IB2021/058056 WO2022049531A1 (en) | 2020-09-03 | 2021-09-03 | Process for the preparation of colostrum concentrate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP4208032A1 true EP4208032A1 (de) | 2023-07-12 |
Family
ID=73139295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP21778224.2A Pending EP4208032A1 (de) | 2020-09-03 | 2021-09-03 | Verfahren zur herstellung von kolostrumkonzentrat |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP4208032A1 (de) |
| IT (1) | IT202000020971A1 (de) |
| WO (1) | WO2022049531A1 (de) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ239466A (en) * | 1990-08-17 | 1993-12-23 | Us Agriculture | Desalted colostrum: spray dried product from retentate of |
| CZ279422B6 (cs) * | 1992-04-28 | 1995-04-12 | Biofeed S.R.O. | Způsob přípravy krmných směsí, krmných doplňků, popřípadě poživatin |
| AU6847894A (en) * | 1993-06-23 | 1995-01-17 | Viable Bioproducts Ltd. | Method for the improvement of wound healing and compositions therefor |
| IT1291340B1 (it) * | 1997-05-09 | 1999-01-07 | Vander Way Limited | Formulazioni farmaceutiche contenenti colostro e uso del colostro per il trattamento di affezioni del cavo orale |
| CN1059128C (zh) * | 1997-08-28 | 2000-12-06 | 王文荣 | 含有特异性免疫球蛋白的乳粉及其生产方法 |
-
2020
- 2020-09-03 IT IT102020000020971A patent/IT202000020971A1/it unknown
-
2021
- 2021-09-03 EP EP21778224.2A patent/EP4208032A1/de active Pending
- 2021-09-03 WO PCT/IB2021/058056 patent/WO2022049531A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IT202000020971A1 (it) | 2022-03-03 |
| WO2022049531A1 (en) | 2022-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS6011424A (ja) | 繊維芽細胞成長因子の精製および特性表示 | |
| JP4260877B2 (ja) | ウイルスの不活性化方法 | |
| JP4688092B2 (ja) | 活性型ＴＧＦ−βが濃縮されたタンパク質画分を得る方法、タンパク質画分および治療的適用 | |
| US8993733B2 (en) | Procedure for obtaining a composition containing growth factors from a blood compound, and composition obtained by said procedure | |
| RU2366294C1 (ru) | Способ получения биологически активной добавки "мобелиз" и полученная этим способом бад "мобелиз" | |
| WO2022049531A1 (en) | Process for the preparation of colostrum concentrate | |
| NO163959B (no) | Fremgangsm te for utvinning og rensing av et polype | |
| WO2019187200A1 (ja) | 成長因子混合物およびその調製方法 | |
| US4882421A (en) | Pharmaceutical for treating tumors and method for making it | |
| AU681872B2 (en) | Keyhole limpet hemocyanin composition with enhanced anti-tumor activity against bladder cancer | |
| EP3411384B1 (de) | Extraktionsverfahren aus kolostrum | |
| Jadhav et al. | Antivenin production in India | |
| CN106167797B (zh) | 人纤维蛋白溶解酶原的冻干制剂及其制备方法 | |
| NO793412L (no) | Fremgangsmaate for fremstilling av overfoeringsfaktor mot patogene antigener | |
| Elrick et al. | Collection, processing and fractionation of human pituitary glands | |
| EP3177636B1 (de) | Verfahren zur herstellung von hochreinen mischungen von proteinfaktoren aus rinderkolostrum | |
| TWI645038B (zh) | 可提升幹細胞存活率之胎盤活性成分製備方法 | |
| RU2397672C1 (ru) | Способ комплексной переработки топинамбура | |
| KR20190142826A (ko) | 뱀독의 독성 성분이 분리된 분리정제뱀독의 제조방법 | |
| CA2814180C (en) | A method of preserving growth factors derived from platelets | |
| RU2828386C1 (ru) | Способ получения экстракта из плаценты человека | |
| RU2399629C1 (ru) | Способ комплексной переработки топинамбура | |
| RU2318406C1 (ru) | Способ получения бад из низкомолекулярных катионных белков молока и полученная этим способом бад | |
| CN105420330B (zh) | 孔鳐软骨蛋白抗氧化肽的制备方法 | |
| CN104606231A (zh) | 一种促肝细胞生长素原液及冻粉针剂的制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20230324 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20240422 |